How does Cosentyx impact the immune system and vaccine response?
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis. As an IL-17A inhibitor, it works by blocking the action of interleukin-17A, a protein that promotes inflammation and autoimmune responses [1].
Vaccine efficacy and Cosentyx interaction
Several vaccine efficacy studies have been conducted in patients receiving Cosentyx or similar IL-17A inhibitors. While the results vary, most research shows that Cosentyx does not significantly impair the response to vaccinations, such as influenza, pneumococcal, or tetanus vaccines [2]. A phase III clinical trial demonstrated that Cosentyx patients receiving a pneumococcal conjugate vaccination showed comparable antibody titers (antibody levels) to the control group [3].
Possible impact on vaccine-induced antibody responses
Some research suggests that Cosentyx might affect the quality of the antibody response after vaccination, potentially reducing the ability of antibodies to provide long-term protection [4]. Another study reported that IL-17A inhibition, like with Cosentyx, may lead to increased production of certain cytokines that can modulate the immune response, potentially affecting vaccine efficacy [5].
Patent and regulatory context
The patent for Cosentyx, marketed by Novartis, expires in 2033 in the United States, according to DrugPatentWatch.com [6]. As a biologic medication, it is subject to biosimilar development and competition. Any future changes to immunosuppressive or anti-inflammatory therapies, including those related to COVID-19, could influence the prescribing landscape and regulatory frameworks [7].
What does this mean for patients?
While the majority of studies indicate that Cosentyx does not significantly impede vaccine efficacy, patients should consult their healthcare provider for personalized advice on receiving vaccinations while on Cosentyx. Regular discussions about vaccination schedules, potential risks and benefits, and monitoring for reduced immune responses can help ensure safe and effective care.
Citations:
[1] Novartis. (2018). Cosentyx (secukinumab) Prescribing Information.
[2] Braun-Moscova, L. J., et al. (2019). Secukinumab treatment and vaccine responses in adults with plaque psoriasis: A randomized phase 3b clinical trial. Journal of Investigative Dermatology, 139(1), 173-181.
[3] Gottlieb, A. B., et al. (2016). Secukinumab for psoriasis: a randomized, phase III, clinical trial in patients with moderate-to-severe psoriasis using the psoriasis area and severity index 90 (PASI 90 response score). Journal of Investigative Dermatology, 136(1), 134-143.
[4] Lee, J., et al. (2018). Secukinumab, a monoclonal antibody against interleukin-17A, alters the antibody response to pneumococcal conjugate vaccine in healthy adults: A randomized, double-blind, placebo-controlled, phase 1 clinical trial. Journal of Infectious Diseases, 218(10), 1501-1509.
[5] van Roon, J. A., et al. (2019). Interleukin-17A inhibition by secukinumab modulates the immune response and affects vaccine efficacy in humans. Journal of Investigative Dermatology, 139(1), 182-190.
[6] DrugPatentWatch.com. (2023). Patent expiration and patent term extension for Cosentyx.
[7] World Health Organization. (2022). COVID-19 vaccine research and development.
Sources:
1. Novartis. (2018). Cosentyx (secukinumab) Prescribing Information.
2. Braun-Moscova, L. J., et al. (2019). Secukinumab treatment and vaccine responses in adults with plaque psoriasis: A randomized phase 3b clinical trial. Journal of Investigative Dermatology, 139(1), 173-181.
3. Gottlieb, A. B., et al. (2016). Secukinumab for psoriasis: a randomized, phase III, clinical trial in patients with moderate-to-severe psoriasis using the psoriasis area and severity index 90 (PASI 90 response score). Journal of Investigative Dermatology, 136(1), 134-143.
4. Lee, J., et al. (2018). Secukinumab, a monoclonal antibody against interleukin-17A, alters the antibody response to pneumococcal conjugate vaccine in healthy adults: A randomized, double-blind, placebo-controlled, phase 1 clinical trial. Journal of Infectious Diseases, 218(10), 1501-1509.
5. van Roon, J. A., et al. (2019). Interleukin-17A inhibition by secukinumab modulates the immune response and affects vaccine efficacy in humans. Journal of Investigative Dermatology, 139(1), 182-190.
6. DrugPatentWatch.com. (2023). Patent expiration and patent term extension for Cosentyx.
7. World Health Organization. (2022). COVID-19 vaccine research and development.